RGNX
Price
$5.89
Change
+$0.48 (+8.87%)
Updated
Apr 11 closing price
Capitalization
271.13M
18 days until earnings call
VRDN
Price
$12.02
Change
+$0.61 (+5.35%)
Updated
Apr 11 closing price
Capitalization
979.45M
25 days until earnings call
Ad is loading...

RGNX vs VRDN

Header iconRGNX vs VRDN Comparison
Open Charts RGNX vs VRDNBanner chart's image
REGENXBIO
Price$5.89
Change+$0.48 (+8.87%)
Volume$1.22M
Capitalization271.13M
Viridian Therapeutics
Price$12.02
Change+$0.61 (+5.35%)
Volume$1.21M
Capitalization979.45M
RGNX vs VRDN Comparison Chart
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. VRDN commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and VRDN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (RGNX: $5.89 vs. VRDN: $12.02)
Brand notoriety: RGNX and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 129% vs. VRDN: 125%
Market capitalization -- RGNX: $271.13M vs. VRDN: $979.45M
RGNX [@Biotechnology] is valued at $271.13M. VRDN’s [@Biotechnology] market capitalization is $979.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, RGNX is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • RGNX’s TA Score: 4 bullish, 6 bearish.
  • VRDN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -6.36% price change this week, while VRDN (@Biotechnology) price change was +0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

RGNX is expected to report earnings on Jul 30, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($979M) has a higher market cap than RGNX($271M). RGNX YTD gains are higher at: -23.803 vs. VRDN (-37.298). RGNX has higher annual earnings (EBITDA): -198.23M vs. VRDN (-266.36M). VRDN has more cash in the bank: 718M vs. RGNX (235M). VRDN has less debt than RGNX: VRDN (21.1M) vs RGNX (82M). RGNX has higher revenues than VRDN: RGNX (83.3M) vs VRDN (302K).
RGNXVRDNRGNX / VRDN
Capitalization271M979M28%
EBITDA-198.23M-266.36M74%
Gain YTD-23.803-37.29864%
P/E RatioN/AN/A-
Revenue83.3M302K27,583%
Total Cash235M718M33%
Total Debt82M21.1M389%
FUNDAMENTALS RATINGS
RGNX vs VRDN: Fundamental Ratings
RGNX
VRDN
OUTLOOK RATING
1..100
6553
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
8992
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (76) in the Biotechnology industry is in the same range as VRDN (89). This means that RGNX’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as RGNX (100). This means that VRDN’s stock grew similarly to RGNX’s over the last 12 months.

VRDN's SMR Rating (94) in the Biotechnology industry is in the same range as RGNX (95). This means that VRDN’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (89) in the Biotechnology industry is in the same range as VRDN (92). This means that RGNX’s stock grew similarly to VRDN’s over the last 12 months.

RGNX's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for VRDN (100). This means that RGNX’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXVRDN
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 25 days ago
75%
Bullish Trend 27 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAFCX17.60N/A
N/A
Lord Abbett Affiliated C
IPESX5.61N/A
N/A
Voya Large Cap Value Port S
IVSOX18.99N/A
N/A
Voya SmallCap Opportunities Port I
CBARX42.45N/A
N/A
Calvert Balanced R6
BIDEX10.00N/A
N/A
BlackRock Defensive Advantage EM Instl

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with RCKT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+8.87%
RCKT - RGNX
56%
Loosely correlated
+6.68%
DNLI - RGNX
54%
Loosely correlated
+1.60%
NTLA - RGNX
49%
Loosely correlated
+9.45%
ACAD - RGNX
49%
Loosely correlated
+3.33%
AXON - RGNX
48%
Loosely correlated
+3.03%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+5.35%
DNLI - VRDN
50%
Loosely correlated
+1.60%
FATE - VRDN
47%
Loosely correlated
+15.27%
AURA - VRDN
47%
Loosely correlated
+6.64%
TERN - VRDN
46%
Loosely correlated
N/A
RGNX - VRDN
45%
Loosely correlated
+8.87%
More